REG - Theracryf PLC - Passing of Dr Sue Foden, Chair

TheracryfAnnouncement

04/11/2024 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241104:nRSD8273Ka&default-theme=true

RNS Number : 8273K  Theracryf PLC  04 November 2024

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Passing of  Dr Sue Foden, Chair

Alderley Park, UK - 4 November 2024: TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on oncology and neuropsychiatry
announces with deep sadness the sudden passing of Dr Sue Foden, the Company's
Chair.

Sue was appointed as a non-executive director to TheraCryf plc (then Evgen
Pharma plc) in 2015, becoming Chair in September 2023. Over the past nine
years, she has been a valuable advisor and support to the leadership team and
Company overall. Her passing is a great loss to the Biotech sector in the UK
and beyond.

The Company will seek an additional non-executive director as soon as
practicable. Our thoughts are with Sue's family during this difficult time.

Dr Huw Jones, CEO, said:

"On behalf of the Board and all my colleagues at TheraCryf I wanted to express
our collective shock and sadness at the news of Sue's passing. Over the years,
she showed deep passion and dedication to supporting TheraCryf and its team.
Her fierce intellect, deep scientific insights, support and guidance were very
important to me and she will be missed by us all."

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Vigo Consulting                                             +44 207 7390 0230
 Rozi Morris
theracryf@vigoconsulting.com

 

About TheraCryf

TheraCryf is a clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma*, neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan indications].

Its strategy is to generate compelling data sets to preclinical and/or
clinical proof of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. The Company has sourced
know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and University of Connecticut.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSIFSLELSEIF